## Q: Our diabetes research lab needs to measure mitochondrial function in patient PBMCs. Which Agilent instrument fits and which trials have used it?

**Route** (gpt-5.4-mini, 1.5s): clinical: The request is entirely about Agilent clinical/research instruments and diabetes-related studies using them, so it only needs the Clinical Agent. (confidence 0.98)

### Clinical Agent (34.7s)
*Sub-question:* For a diabetes research lab measuring mitochondrial function in patient PBMCs, which Agilent instrument is the best fit (e.g., Seahorse XF platform), and which clinical trials or diabetes-related studies have used that instrument on PBMCs? Please include model-specific fit and any relevant caveats about sample type, assay constraints, and trial/study examples.

Best fit: an Agilent Seahorse XF platform—preferably a 96-well Seahorse XFe/XF Pro configuration if the lab expects repeated patient-PBMC cohorts and needs OCR/ECAR, mitochondrial stress, substrate oxidation, glycolysis, and ATP-production readouts. This is a research-use metabolic phenotyping fit, not a diagnostic diabetes test; PBMC viability, cell number, adherence/immobilization, isolation timing, and cryopreservation effects are critical caveats. ClinicalTrials.gov records show multiple diabetes/metabolic studies using Seahorse on PBMCs or monocytes, including NCT03854656, NCT04293224, NCT03078101, NCT05970601, NCT03441919, and NCT04193566.

**Findings**
- (✅ confirmed) Agilent Seahorse XF analyzers are intended for real-time, label-free measurement of cellular respiration, glycolysis, and ATP production in live cell models, matching a diabetes PBMC mitochondrial-function workflow focused on OCR/ECAR and metabolic phenotyping. [S9, S36]
- (✅ confirmed) For model-specific fit, the trial evidence most directly supports a 96-well Seahorse configuration for PBMC/monocyte metabolic assays: NCT05673837 specifies Seahorse XFe96 Analyzer for OCR and lactate production in diabetes-related bone cells, and NCT04193566 specifies Seahorse X96 analyzer for peripheral blood monocyte mitochondrial function. [S19, S25]
- (✅ confirmed) PBMC-specific diabetes/metabolic trials used Seahorse to measure mitochondrial respiration or OCR/ECAR: NCT03854656 measured respiratory and glycolytic capacities of isolated PBMCs using the Seahorse method in overweight individuals at high risk of type 2 diabetes; NCT04293224 measured PBMC OCR and ECAR using a Seahorse XF Analyzer; NCT03078101 measured OCR and ECAR in PBMCs by Seahorse Flux Analyzer. [S22, S23, S24]
- (✅ confirmed) Additional diabetes-dataset trial examples include NCT05970601, which analyzes mitochondrial respiration capacity via Seahorse technology in isolated PBMCs after sodium/potassium salt intake, and NCT03441919, which measures intracellular metabolism/mitochondrial stress test OCR by Seahorse respirometer in type 1 diabetes innate immune activation. [S20, S21]
- (✅ confirmed) Seahorse use is common enough in the diabetes ClinicalTrials.gov export to support it as a field-accepted research method: the instrument-usage search found 11 Seahorse-mentioning trials overall, 9 in the diabetes dataset, with 7 completed and others recruiting/not-yet-recruiting/unknown/withdrawn. [S17, S18, S19, S20, S21, S22, S23, S24, S25, S26, S27]
- (✅ confirmed) PBMC sample constraints are material: one trial explicitly cryopreserves PBMCs before Seahorse XF substrate oxidation stress testing, while several diabetes trials specify isolated PBMCs and timing from baseline to follow-up or acute time points, implying the lab must control isolation, storage, and timing variables. [S17, S21, S22, S23, S24]
- (✅ confirmed) The Agilent product source does not state IVD clearance for Seahorse XF analyzers, while Agilent’s NanoZoomer page explicitly states IVD for digital pathology; therefore Seahorse XF should be treated as a research-use metabolic analyzer and not used to diagnose diabetes in individual patients unless local regulatory claims are independently verified. [S9, S11, S36, S38]
- (✅ confirmed) Diabetes literature in the provided knowledge base emphasizes glucose/HbA1c and related clinical biomarkers for diagnosis/management rather than Seahorse PBMC assays; PBMC Seahorse is therefore best framed as mechanistic or translational biomarker research, not routine clinical diabetes testing. [S1, S2, S14, S16]

**Recommendations**
- **[high] Select an Agilent Seahorse XF 96-well platform—XFe96/XF Pro class—for patient PBMC mitochondrial-function studies, unless your cohort volume is very small and lower-throughput formats are already validated in your lab.**: The measurement need is live-cell OCR/ECAR, glycolysis/oxidative phosphorylation, ATP production, and mitochondrial stress/substrate-oxidation profiling; diabetes/metabolic trial records show PBMC or monocyte Seahorse use, and two records specify 96-well Seahorse models. [S9, S19, S21, S22, S23, S24, S25, S36]
- **[high] Design the PBMC workflow around fresh-vs-cryopreserved comparability, viable cell recovery, standardized isolation, and consistent time from draw to assay.**: Clinical trial examples use isolated PBMCs, acute timepoints, longitudinal visits, and in one case cryopreserved PBMCs, all of which can alter respiration and should be controlled or validated. [S17, S21, S22, S23]
- **[high] Use OCR, ECAR, basal respiration, mitochondrial stress-test parameters, and/or substrate oxidation endpoints as research biomarkers rather than diagnostic endpoints.**: Seahorse XF measures respiration/glycolysis/ATP production, but the product source does not state an IVD diagnostic claim; diabetes diagnosis/management in the supplied literature centers on glucose and HbA1c-related biomarkers. [S1, S2, S9, S14, S16, S36]
- **[medium] Benchmark your protocol against diabetes/metabolic trial examples: NCT03854656, NCT04293224, NCT03078101, NCT05970601, NCT03441919, and NCT04193566.**: These records provide concrete precedent for Seahorse-based PBMC or peripheral monocyte mitochondrial/metabolic measurements in diabetes or diabetes-adjacent metabolic studies. [S20, S21, S22, S23, S24, S25]
- **[low] If you also need tissue pathology, keep that workflow separate: NanoZoomer IVD is appropriate for histopathology slide imaging, but it does not answer PBMC mitochondrial function questions.**: NanoZoomer is an IVD whole-slide scanner for glass/anatomical tissue slides, whereas Seahorse XF is the metabolic analyzer matching PBMC respiration/glycolysis measurements. [S9, S11, S36, S38]

**Next steps**
- Confirm expected PBMC samples per week, replicate strategy, and whether assays will be run fresh, cryopreserved, or both.
- Choose the assay panel: mitochondrial stress test, glycolytic rate/stress test, ATP rate assay, and/or substrate oxidation stress test.
- Run a PBMC feasibility study to define minimum cell number per well, acceptable viability, coefficient of variation, and post-thaw performance.
- Map clinical metadata to assay timing: fasting state, medication class such as SGLT2 inhibitors, insulin use, BMI, infection/inflammation status, and time of blood draw.
- Use trial records NCT03854656, NCT04293224, NCT03078101, NCT05970601, NCT03441919, and NCT04193566 as protocol precedents, but do not assume trial results unless the records report them.
- Verify current Agilent model availability, service coverage, software, consumable supply, and any local regulatory labeling directly with Agilent before purchase.

**Information needed from you**
- PBMC sample volume available per patient and expected viable cell yield.
- Fresh versus cryopreserved workflow preference and maximum time from venipuncture to assay.
- Number of patient cohorts, samples per week, and desired technical/biological replicates.
- Specific endpoints needed: OCR only, OCR/ECAR, ATP rate, substrate oxidation, ROS/membrane potential add-ons, or cytokine integration.
- Regulatory intent: research publication, exploratory clinical trial biomarker, CLIA/LDT development, or diagnostic use.
- Budget, service-contract expectations, available operators, and existing cell-culture/instrument infrastructure.

**Risks and assumptions**
- Assumption: the lab’s goal is mechanistic diabetes research or exploratory biomarker work, not clinical diagnosis.
- Risk: PBMC heterogeneity, activation during isolation, and disease/medication effects can confound mitochondrial readouts.
- Risk: cryopreservation may alter Seahorse readouts; if used, it needs validation against fresh PBMCs.
- Risk: Seahorse XF product source does not state IVD clearance, so diagnostic claims should not be made from PBMC Seahorse data alone.
- Risk: ClinicalTrials.gov records show intended measurements and outcomes, not necessarily validated performance or published results.

**How to measure impact (KPIs)**
- Assay precision: Track intra-plate and inter-day CVs for PBMC basal OCR, maximal respiration, spare respiratory capacity, and ECAR across healthy donor controls.
- Sample success rate: Percentage of patient PBMC samples meeting predefined viability, cell recovery, and respiration quality-control thresholds.
- Throughput: Number of patient samples completed per Seahorse run and per week, including controls and technical replicates.
- Protocol robustness: Compare fresh versus cryopreserved PBMC OCR/ECAR profiles and quantify bias, variance, and failed wells.
- Translational signal detection: Predefine diabetes cohort contrasts or intervention-related changes and estimate effect sizes for OCR/ECAR endpoints.

**Confidence:** high: The core recommendation is directly supported by Agilent Seahorse product information and multiple ClinicalTrials.gov records documenting Seahorse use for PBMC/monocyte OCR, ECAR, and mitochondrial respiration in diabetes or metabolic studies. Model selection is medium-to-high because sources explicitly mention XFe96/X96 in related diabetes records, but final configuration depends on the lab’s throughput and assay format.

*Grounding:* 38 sources, 8 confirmed / 0 hypotheses, citation coverage 100%, grounding score 0.79
*Tools used:* `search_knowledge`, `search_knowledge`, `instrument_usage`, `search_trials`, `recommend_products`

**Sources cited**
- **S1**: Exploring Biomarker Relationships in Both Type 1 and Type 2 Diabetes Mellitus Through a Bayesian Network Analysis Approach, p.2 `data/Clinical/Diabetes/Exploring_Biomarker_Relationships_in_Both_Type_1_and_Type_2_Diabetes_Mellitus_Through_a_Bayesian_Network_Analysis_Approach.pdf`
- **S2**: Deep Learning-Based Genetic Detection and Pathogenesis of Diabetes, p.1 `data/Clinical/Diabetes/Deep_Learning-Based_Genetic_Detection_and_Pathogenesis_of_Diabetes.pdf`
- **S9**: Agilent product page: Seahorse XF analyzers (XF Pro) <https://www.agilent.com/about/newsroom/presrel/2023/07mar-ca23010.html>
- **S11**: Agilent product page: NanoZoomer Slide Scanner System IVD <https://www.agilent.com/en/product/digital-pathology/digital-pathology-scanners/nanozoomer-slide-scanner-system-4370282>
- **S14**: Artificial Intelligence and Machine Learning for Improving Glycemic Control in Diabetes Best Practices Pitfalls and Opportunities, p.1 `data/Clinical/Diabetes/Artificial_Intelligence_and_Machine_Learning_for_Improving_Glycemic_Control_in_Diabetes_Best_Practices_Pitfalls_and_Opportunities.pdf`
- **S16**: Artificial Intelligence and Machine Learning for Improving Glycemic Control in Diabetes Best Practices Pitfalls and Opportunities, p.2 `data/Clinical/Diabetes/Artificial_Intelligence_and_Machine_Learning_for_Improving_Glycemic_Control_in_Diabetes_Best_Practices_Pitfalls_and_Opportunities.pdf`
- **S17**: NCT07134673: Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients <https://clinicaltrials.gov/study/NCT07134673>
- **S18**: NCT06680635: Effect of Citrus Flavonoids on Obesity. <https://clinicaltrials.gov/study/NCT06680635>
- **S19**: NCT05673837: the Type ONe dIabetic Bone Collaboration Study <https://clinicaltrials.gov/study/NCT05673837>
- **S20**: NCT03441919: Activation Innate Immune System in Type 1 Diabetes <https://clinicaltrials.gov/study/NCT03441919>
- **S21**: NCT05970601: Effects of Sodium Chloride or Its Substitute Salt Potassium Chloride on Vascular Function <https://clinicaltrials.gov/study/NCT05970601>
- **S22**: NCT03854656: Effect of Time-restricted Eating on Behaviour and Metabolism in Overweight Individuals at High Risk of Type 2 Diabetes <https://clinicaltrials.gov/study/NCT03854656>
- **S23**: NCT04293224: Metabolic and Bio-behavioral Effects of Following Recommendations in the Dietary Guidelines for Americans <https://clinicaltrials.gov/study/NCT04293224>
- **S24**: NCT03078101: EMPRA (EMPagliflozin and RAs in Kidney Disease) <https://clinicaltrials.gov/study/NCT03078101>
- **S25**: NCT04193566: Acute Effects of SGLT2 Inhibition on Renal Oxygenation and Autonomic Function in Type 1 Diabetes <https://clinicaltrials.gov/study/NCT04193566>
- **S26**: NCT02926079: Investigation of Mechanisms for Transmission of Impaired Glucose Metabolism in Infants Exposed to Diabetes in Utero <https://clinicaltrials.gov/study/NCT02926079>
- **S27**: NCT02995512: Mechanistic Effects of Colchicine in Patients With Myocardial Infarction <https://clinicaltrials.gov/study/NCT02995512>
- **S36**: Catalog: Seahorse XF analyzers (XF Pro) <https://www.agilent.com/about/newsroom/presrel/2023/07mar-ca23010.html>
- **S38**: Catalog: NanoZoomer Slide Scanner System IVD <https://www.agilent.com/en/product/digital-pathology/digital-pathology-scanners/nanozoomer-slide-scanner-system-4370282>

*Total time: 36.2s*